Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise for tough blood cancer

NCT ID NCT02159755

First seen Jan 10, 2026 · Last updated May 01, 2026 · Updated 21 times

Summary

This early-stage trial tested two drugs, ibrutinib and palbociclib, together in 28 people whose mantle cell lymphoma had come back after prior treatment. The goal was to find the safest dose and see how well the combination shrinks tumors. Both drugs block enzymes that cancer cells need to grow, and palbociclib may make cancer cells more sensitive to ibrutinib.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.